Amneal Pharmaceuticals (AMRX) Long-Term Debt Repayments (2017 - 2025)
Historic Long-Term Debt Repayments for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to $2.6 billion.
- Amneal Pharmaceuticals' Long-Term Debt Repayments rose 458628.77% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 67451.24%. This contributed to the annual value of -$188.9 million for FY2024, which is 5437.64% up from last year.
- Per Amneal Pharmaceuticals' latest filing, its Long-Term Debt Repayments stood at $2.6 billion for Q3 2025, which was up 458628.77% from $15.5 million recorded in Q2 2025.
- In the past 5 years, Amneal Pharmaceuticals' Long-Term Debt Repayments ranged from a high of $2.6 billion in Q3 2025 and a low of -$565.6 million during Q4 2023
- Its 5-year average for Long-Term Debt Repayments is $115.2 million, with a median of $25.0 million in 2021.
- Per our database at Business Quant, Amneal Pharmaceuticals' Long-Term Debt Repayments tumbled by 14710.12% in 2023 and then soared by 458628.77% in 2025.
- Over the past 5 years, Amneal Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at -$146.3 million in 2021, then crashed by 56.42% to -$228.9 million in 2022, then tumbled by 147.1% to -$565.6 million in 2023, then skyrocketed by 43.02% to -$322.3 million in 2024, then soared by 892.52% to $2.6 billion in 2025.
- Its Long-Term Debt Repayments was $2.6 billion in Q3 2025, compared to $15.5 million in Q2 2025 and $235.5 million in Q1 2025.